Radiopharmaceutical · Cytotoxic, directed at fibroblast activation protein (FAP) (FAP) · developed by Perspective Therapeutics
Pb-PSV359 is a lead-labeled radiopharmaceutical that targets fibroblast activation protein (FAP), which is expressed on FAP-positive cancers. The 203Pb form is given for single-photon emission computed tomography imaging, and the 212Pb form is given by intravenous infusion for treatment of FAP-expressing cancers, including pancreatic, gastric, esophageal, colorectal, ovarian, head and neck cancers, sarcoma and mesothelioma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06710756 | Phase 1/2 | Pancreatic Ductal Adenocarcinoma | Recruiting | CATX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerEsophageal CancerGastric CancerHead and Neck CancerMesotheliomaOvarian CancerPancreatic Ductal AdenocarcinomaSarcoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the CATX page.
See CATX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CATX catalysts and pipeline →